CNBX Pharmaceuticals (CNBX) Net Cash Flow (2016 - 2025)
CNBX Pharmaceuticals (CNBX) has disclosed Net Cash Flow for 13 consecutive years, with -$7408.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow rose 18.39% year-over-year to -$7408.0, compared with a TTM value of -$9636.0 through Nov 2025, up 85.02%, and an annual FY2025 reading of -$11305.0, up 89.05% over the prior year.
- Net Cash Flow was -$7408.0 for Q4 2025 at CNBX Pharmaceuticals, down from $1463.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $1.2 million in Q1 2021 and bottomed at -$600058.0 in Q4 2021.
- Average Net Cash Flow over 5 years is -$8573.8, with a median of -$8242.5 recorded in 2024.
- Peak annual rise in Net Cash Flow hit 2773.26% in 2024, while the deepest fall reached 499.26% in 2024.
- Year by year, Net Cash Flow stood at -$600058.0 in 2021, then surged by 84.02% to -$95915.0 in 2022, then surged by 49.9% to -$48049.0 in 2023, then skyrocketed by 81.11% to -$9077.0 in 2024, then increased by 18.39% to -$7408.0 in 2025.
- Business Quant data shows Net Cash Flow for CNBX at -$7408.0 in Q4 2025, $1463.0 in Q3 2025, and -$32027.0 in Q2 2025.